UID:
almafu_9959076716002883
Format:
1 online resource (177 p.)
ISBN:
3-318-02169-5
Series Statement:
Advances in cardiology,
Content:
Platelets play a critical role in the pathophysiology of acute coronary syndromes (ACS) and thromboembolic complications associated with atrial fibrillation. Anticoagulant and antiplatelet therapies are central to the treatment of ACS and atrial fibrillation. Over the last several decades, a better understanding of the pathogenesis of coronary heart disease and atrial fibrillation has led to refinements in antithrombotic strategies and clinical outcomes. With this in mind, some of the issues outlined in this book are new insights in genetic testing and modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers. Most importantly, the current update of pros and cons of novel antiplatelet agents such as prasugrel and ticagrelor are provided in detail. Conventional antiplatelet strategies with aspirin and clopidogrel are also discussed. Special attention is devoted to experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers. The ability to focus on different diseases beyond ACS, including heart failure and atrial fibrillation, distinguishes this publication. Each chapter was written by top experts in the field and scientists with the utmost authority and expertise to provide cardiologists, internists, and clinical pharmacologists with the latest updates.
Note:
Description based upon print version of record.
,
""Cover""; ""Front Matter""; ""Contents""; ""Introduction""; ""References""; ""Impact of Antiplatelet Therapy in Heart Disease""; ""Abstract""; ""Acute Coronary Syndromes""; ""Atrial Fibrillation""; ""References""; ""Antiplatelet Therapy in Acute Coronary Syndrome and Atrial Fibrillation: Aspirin""; ""Abstract""; ""Mechanism of Action""; ""Pharmacokinetics""; ""Dosage""; ""Side Effects""; ""Aspirin Resistance""; ""Aspirin in Acute Coronary Syndrome""; ""Conclusion""; ""References""; ""Clopidogrel in Coronary Artery Disease: Update 2012""; ""Abstract""
,
""Clopidogrel in Stable/Elective Patients Referred for Percutaneous Coronary Interventions""""Clopidogrel in Non- ST-Segment Elevation Myocardial Infarction (NSTEMI)""; ""Clopidogrel in ST-Segment Elevation Myocardial Infarction (STEMI)""; ""Frequently Discussed Topics When Clopidogrel Is Used""; ""Duration of Dual Antiplatelet Therapy""; ""Conclusion""; ""References""; ""Prasugrel""; ""Abstract""; ""Prasugrel: Pharmacokinetics, Pharmacodynamics, and Drug Interactions""
,
""Prasugrel in High- Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The TRITON- TIMI 38 Trial""""Impact of Prasugrel on Early and Late Events""; ""Prasugrel and Reduction of Ischemic Events: Myocardial Infarction and Stent Thrombosis""; ""Recurrent Events""; ""Specific Populations: ST-Elevation Myocardial Infarction, Diabetes, Vulnerable Patients, and Coronary Artery Bypass Grafting""; ""Cost-Effectiveness""; ""Prasugrel: Ongoing Studies""; ""Conclusions""; ""References""; ""Antiplatelet Therapy in Acute Coronary Syndromes: Ticagrelor""; ""Abstract""
,
""Ticagrelor""""PLATO Trial Design""; ""PLATO Baseline Characteristics and Randomized Treatment""; ""PLATO Trial Results � Efficacy""; ""PLATO Subanalyses""; ""PLATO Trial Results � Safety""; ""Additional Ticagrelor Studies in Patients with Ischemic Heart Disease""; ""Conclusions""; ""Disclosure Statement""; ""References""; ""Dipyridamole in Antithrombotic Treatment""; ""Abstract""; ""Antithrombotic Rather than Antiplatelet Activity by Dipyridamole""; ""The Importance of Sufficient Plasma Concentration""; ""Protecting Tissue � Pleiotropic Effects""; ""Inhibition of Thrombin Formation""
,
""Inhibition of Smooth Muscle Cell Proliferation � Prevention of Restenosis""""Inhibiting Innate Inflammation""; ""Conclusion""; ""References""; ""Protease-Activated Receptor-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Acute Coronary Syndrome""; ""Abstract""; ""Rationale for Developing PAR-1 Inhibitors""; ""Protease-Activated Receptor-1 Inhibitors in Advanced Clinical Development: Vorapaxar and Atopaxar""; ""Phase II of Vorapaxar""; ""Ongoing Phase III of Vorapaxar""; ""Phase II of Atopaxar""; ""Conclusions""; ""References""
,
""Genetic Considerations""
,
English
Additional Edition:
ISBN 3-318-02168-7
Language:
English
Bookmarklink
